Syremis Therapeutics

Syremis Therapeutics is a clinical-stage biopharmaceutical company developing drugs with the potential to profoundly impact the treatment of mental health disorders. The company’s neuropsychiatry pipeline is rooted in emerging markets and clinically validated mechanisms of action, including muscarinic M1/M4 agonism and next-generation NMDA modulation. Syremis’ lead program, ST-905, is an M1/M4 dual agonist in Phase 1 development for schizophrenia and other psychiatric conditions.